The South San Francisco-based clinical-stage drug discovery, development, and manufacturing company is advancing next-generation oncology therapeutics, including STRO-001 and STRO-002, its first two internally-developed ADCs. STRO-001 is a CD74-targeting ADC currently under investigation in a Phase 1 clinical trial for patients with advanced B-cell malignancies, while STRO-002 is a folate receptor alpha (FolRα)-targeting ADC currently being investigated in a Phase 1 clinical trial for patients with ovarian and endometrial cancers. Sutro's collaboration with Bristol Myers Squibb and Merck KGaA has resulted in two additional product candidates, CC-99712 and M1231, respectively, which are enrolling patients for their Phase 1 clinical trials. Sutro is entitled to milestone or contingent payments and tiered royalties from these collaborations.